

1 **SARS-CoV-2 Omicron symptomatic infections in previously infected or vaccinated South**  
2 **African healthcare workers**

3 Marta C. Nunes<sup>1,2</sup>, Sthembile Sibanda<sup>1,2</sup>, Vicky L. Baillie<sup>1,2</sup>, Gaurav Kwatra<sup>1,2</sup>, Ricardo Aguas<sup>3</sup>,  
4 Shabir A. Madhi<sup>1,2,4</sup>, for the Wits VIDA HCW Study Group

5 <sup>1</sup>South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research  
6 Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand,  
7 Johannesburg, South Africa; <sup>2</sup>Department of Science and Technology/National Research  
8 Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of  
9 Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; <sup>3</sup>Centre for  
10 Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford,  
11 Oxford, United Kingdom; <sup>4</sup>African Leadership in Vaccinology Expertise, Faculty of Health  
12 Sciences, University of the Witwatersrand, Johannesburg, South Africa

13 Corresponding Author: Marta C. Nunes

14 Wits VIDA

15 Chris Hani Road

16 Chris Hani Baragwanath Academic Hospital

17 Wits Learning Centre, 11th Floor West Wing

18 2013 Bertsham, South Africa

19 Phone: +27 11 983 4262, [marta.nunes@wits-vida.org](mailto:marta.nunes@wits-vida.org)

20 Abstract

21 **Abstract**

22 We investigated Omicron infections among healthcare workers (HCW) presenting with  
23 symptoms of SARS-CoV-2 infection and evaluated the protective effect of vaccination or prior  
24 infection.

25 Between 24<sup>th</sup> November and 31<sup>st</sup> December 2021, HCW in Johannesburg, South Africa, were  
26 tested for SARS-CoV-2 infection by Nucleic Acid Amplification Test (NAAT). Blood samples  
27 collected either at the symptomatic visit or within 3-months prior, were tested for spike protein  
28 immunoglobulin G (IgG).

29 Overall, 433 symptomatic HCW were included in the analysis, with 190 (43.9%) having an  
30 Omicron infection; 69 (16.7%) were unvaccinated and 270 (62.4%) received a single dose of  
31 Ad26.COV.2 vaccine. There was no difference in the odds of identifying Omicron between  
32 unvaccinated and Ad26.COV.2 vaccinated HCW (adjusted odds ratio [aOR] 0.81, 95%  
33 confidence interval [CI]: 0.46, 1.43). One-hundred and fifty-four (35.3%) HCW had at least one  
34 SARS-CoV-2 NAAT-confirmed prior infection; these had lower odds of Omicron infection  
35 compared with those without past infection (aOR 0.55, 95%CI: 0.36, 0.84). Anti-spike IgG  
36 concentration of 1549 binding antibody unit/mL was suggestive of significant reduction in the  
37 risk of symptomatic Omicron infection.

38 We found high reinfection and vaccine breakthrough infection rates with the Omicron variant  
39 among HCW. Prior infection and high anti-spike IgG concentration were protective against  
40 Omicron infection.

41 **Keywords:** COVID-19, SARS-CoV-2, Omicron, reinfection, vaccination

## 42 **Introduction**

43 The Omicron (B.1.1.529/21K) severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)  
44 variant was reported in South Africa on 25<sup>th</sup> November 2021, following investigation of a rapid  
45 increase in coronavirus disease (COVID-19) cases in the Gauteng province, and identification of  
46 a spike gene target failure (SGTF) on the Taqpath assay (ThermoFisher™), which also includes  
47 two other gene targets. In December 2021, the Omicron variant constituted 98% of all SARS-  
48 CoV-2 infections in South Africa, and has now spread globally [1].

49 Healthcare workers (HCW) in South Africa were offered the Ad26.COV.2 COVID-19 vaccine as  
50 part of the Sisonke trial from 17<sup>th</sup> February 2021 as a single dose schedule, and subsequently a  
51 booster dose was offered since 8<sup>th</sup> November 2021 [2]. From May 2021, HCW could also access  
52 the BNT162b2 COVID-19 vaccine as part of the national vaccine rollout in South Africa.

53 Here we describe the Omicron infections among HCW who presented with symptoms suggestive  
54 of SARS-CoV-2 infection from 24<sup>th</sup> November to 31<sup>st</sup> December 2021. We also detail  
55 breakthrough infections in vaccinated HCW and reinfections in previous Nucleic Acid  
56 Amplification Test (NAAT)-confirmed SARS-CoV-2 cases. In addition, blood samples collected  
57 either at the symptomatic visit or in the 3-months prior, were tested for full-length SARS-CoV-2  
58 spike protein immunoglobulin G (IgG) to assess the potential protective effect of these  
59 antibodies.

## 60 **Methods**

### 61 **Study design**

62 Healthcare workers (HCW) working at Chris Hani Baragwanath Academic Hospital (CHBAH),  
63 in Johannesburg, Gauteng province, South Africa were enrolled from April to July 2020, into a

64 longitudinal cohort surveillance study, this cohort has been previously described [3]. Due to  
65 participants discontinuing the study, enrolments into the longitudinal cohort were re-started on  
66 16<sup>th</sup> February 2021 and closed on 10<sup>th</sup> August 2021. Among the longitudinal cohort participants,  
67 routine study visits (every 1 to 2 weeks for nasal swab collection and approximately every 4  
68 weeks for nasal swab and venous blood collection) and visits when COVID-like symptoms are  
69 present are still ongoing.

70 From 22<sup>nd</sup> June 2021 HCW from CHBAH, not enrolled into the longitudinal cohort, who  
71 presented with COVID-like symptoms could enrol into a test negative case-control (TNC) study  
72 and be tested for SARS-CoV-2 infection by Nucleic Acid Amplification Test (NAAT) on nasal  
73 swab. On 14<sup>th</sup> December 2021 this was expanded to two other Johannesburg hospitals: Charlotte  
74 Maxeke Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH). HCW  
75 enrolled into the TNC could present for multiple study visits. Enrolments are still ongoing at the  
76 three hospitals. HCW in the longitudinal cohort who were investigated for symptomatic illness  
77 were also eligible for inclusion in the TNC study.

78 Symptoms considered to be consistent with COVID-19 included any of the following:  
79 fever/feeling feverish, cough, sore throat, rhinitis, myalgia, shortness of breath, acute  
80 gastroenteritis/vomiting/nausea, impaired sense of smell or taste, fatigue or headache. If a HCW  
81 had multiple symptomatic study visits between 24<sup>th</sup> November and 31<sup>st</sup> December 2021 only the  
82 visit with a NAAT SARS-CoV-2 positive result was included, or the first symptomatic visit if no  
83 NAAT positive result.

84 Demographic, health and behavioural questionnaires, collected personal information including  
85 COVID-19 vaccination history; previous SARS-CoV-2 infection was determined by documented  
86 NAAT positivity in the cohort participants or self-reporting.

87 Laboratory methods

88 Total nucleic acids were extracted from nasal swabs using an automated NucliSENS-easyMAG  
89 nucleic acid extraction platform. NAAT was performed using the TaqPath COVID-19 diagnostic  
90 test from ThermoFisher that uses a triple-target (orf1ab, N gene, spike gene) design. Results  
91 were classified as positive for SARS-CoV-2 when the 3 targets or when both orf1ab and N gene  
92 had cycle threshold (Ct) values <37 and inconclusive if only one target was detected with Ct  
93 values <37. Results were classified as Omicron variant when orf1ab and N gene were detected  
94 but not the spike gene (SGTF).

95 Serum or plasma samples were collected at approximately monthly intervals from the  
96 longitudinal cohort participants. Participants enrolled into the TNC study had blood samples  
97 collected at enrolment. SARS-CoV-2 full-length spike protein immunoglobulin G (IgG) was  
98 measured by a quantitative assay on the Luminex platform as described [4, 5]. The assay was  
99 evaluated for detection of antibodies against SARS-CoV-2 using COVID-19 convalescent  
100 plasma panel NIBSC 20/118. Based on differences in IgG titers from pre-COVID-19 and  
101 baseline samples when compared to post-infection samples of participants who were SARS-  
102 CoV-2 NAAT positive, 32 binding antibody unit (BAU)/mL was selected as the threshold value  
103 indicative of seropositivity for full-length spike.

104 Statistical analysis

105 Participants' characteristics were described as percentages or means with standard deviations  
106 (SD) or median with interquartile range (IQR) and compared between NAAT-confirmed  
107 Omicron infected and uninfected HCW. The association between Omicron infection, and  
108 vaccination or previous SARS-CoV-2 infection, was estimated by univariate and multivariate

109 logistic regression. Participants were considered fully-vaccinated if they received at least one  
110 dose of Ad26.COV.2 vaccine  $\geq 14$  days before the symptomatic visit or two doses of BNT162b2  
111 vaccine, with the last dose  $\geq 14$  days before the symptomatic visit. Prior SARS-CoV-2 infections  
112 were categorized under the three previous pandemic waves: April to October 2020, November  
113 2020 to April 2021 and May to September 2021. Differences in geometric mean units for spike  
114 IgG between NAAT-confirmed Omicron infected and uninfected HCW were analysed on log<sub>10</sub>-  
115 transformed data.

116 A recursive partitioning approach was performed in the form of conditional inference tree. This  
117 method is particularly good at finding conditional thresholds in covariates by means of  
118 significance tests. Significance tests of the null hypothesis, that Omicron infection risk is  
119 identical on either side of the proposed threshold, are performed at each node of the tree in a  
120 recursive way. The final tree outlines all the splits for which the null hypothesis was rejected,  
121 i.e., for which a difference in outcome is statistically significant with 90% confidence across  
122 merging branches. With this type of conditional partitioning, a training set can be used to find the  
123 relevant splits, after which a validation portion of the data can be used to evaluate the method's  
124 predictive power [6]. This analysis was performed using the rpart, party, and caret R packages.

125 For the purposes of the analyses presented throughout, serological measurements were restricted  
126 to blood samples collected within 3 months of symptomatic visits. If multiple samples were  
127 available, the sample collected closest to the symptomatic visit was used. Participants were  
128 excluded from the serology analysis if they received any vaccine between the last blood draw  
129 and the symptomatic visit or if the last blood draw was  $< 14$  days after the last vaccination. Since  
130 IgG antibodies after natural infection among vaccinated and previous infected individuals can

131 rise quickly, we did a sub-analysis excluding the samples collected on the day of the  
132 symptomatic visit.

### 133 **Results**

134 The first case of SARS-CoV-2 with SGTF among HCW in our study was detected on 24<sup>th</sup>  
135 November 2021, prior to which the last confirmed SARS-CoV-2 infection was on 20<sup>th</sup>  
136 September 2021. From 24<sup>th</sup> November to 31<sup>st</sup> December 2021, 445 HCW had at least one  
137 symptomatic visit where nasal swabs were collected and tested by Taqpath NAAT for SARS-  
138 CoV-2 infection. Nine HCW had inconclusive results and were excluded from the analysis, and  
139 all but three (also excluded from the analysis) of the SARS-CoV-2 infections detected during this  
140 period had NAAT results with SGTF and putatively were Omicron variant.

141 Among the 433 symptomatic HCW included in the analysis, 190 (43.9%) had a positive NAAT.  
142 Overall, 270 (62.4%) received a single dose of Ad26.COV.2 vaccine (median 280-days;  
143 interquartile range [IQR]: 257, 287), and 49 (11.8%) received a booster dose (median of 22-days;  
144 IQR: 18, 33)  $\geq 14$ -days before the symptomatic visit. Only 26 (6.3%) HCW received two doses of  
145 BNT162b2  $\geq 14$ -days before the visit, and 69 (16.7%) were unvaccinated. Vaccination coverage  
146 was similar among HCW with symptomatic illness in whom Omicron was and was not identified  
147 (Table 1). Also, there was no difference in the odds of identifying Omicron between  
148 unvaccinated and vaccinated HCW, although the numbers for BNT162b recipients were low  
149 (Table 2).

150 Overall, 154 (35.6%) HCW had at least one SARS-CoV-2 NAAT-confirmed infection prior to  
151 November 2021, 53 (34.4%) of whom were reinfected with Omicron; compared with 137  
152 Omicron infections among the 279 (49.1%  $p=0.003$ ) HCW without previous NAAT-confirmed

153 infection. Participants with previous NAAT-confirmed infection had lower odds of Omicron  
154 infection compared with those without past infection (adjusted odds ratio [aOR] 0.55, 95%  
155 confidence interval [CI]: 0.36, 0.84). Stratifying by timing of previous infection, infection during  
156 the preceding third wave was associated with lower odds of symptomatic Omicron illness  
157 relative to HCW without any previous NAAT-confirmed infection (aOR 0.40, 95% CI: 0.20,  
158 0.80); likewise, individuals who were infected during the second wave had similar lower odds of  
159 being infected with Omicron during the study period (aOR 0.49, 95% CI: 0.20, 1.23), although  
160 not significant (Table 2).

161 Anti-spike IgG geometric mean units (measured in 267 participants) were lower in HCW who  
162 eventually had an Omicron infection compared with those who never tested positive (577  
163 binding antibody unit [BAU]/mL, vs. 968BAU/mL,  $p=0.009$ ) (Table 1). Excluding blood  
164 samples collected at the time of the current visit, a similar trend in IgG levels was observed  
165 (Table 1).

166 To further investigate which combinations of covariates significantly modulate Omicron  
167 infection, a conditional inference tree was built (Figure-A). Significance was detected in  
168 previous SARS-CoV-2 NAAT-confirmed cases and those with spike IgG levels  $>1549$ BAU/mL  
169 (Figure-B), each with only 33% probability of infection. The boxplots in Figure-C represent the  
170 anti-spike IgG levels by prior SARS-CoV-2 NAAT-confirmed infection and vaccination status.  
171 Overall, IgG concentrations were higher among HCW with prior infection ( $p=0.00015$ ), and in  
172 the group not previously infected in those with more vaccine doses ( $p=0.000057$ ). A lower  
173 significance was detected among the groups with different vaccination status for those who had a  
174 prior confirmed SARS-CoV-2 infection ( $p=0.038$ ).

## 175 **Discussion**

176 We show that prior SARS-CoV-2 infection prevented symptomatic reinfection with Omicron at  
177 45%-60%, what is consistent with results from a large population study in Qatar [7]. Although it  
178 has been suggested that Omicron is evasive to neutralizing antibodies induced by natural  
179 infection from previous variants or vaccine-elicited[8], we show that HCW who were not  
180 infected by Omicron during the five week period of this analysis had higher concentration of  
181 anti-spike IgG prior the symptomatic visit, with >1549BAU/mL being the threshold suggestive  
182 of significant reduction in the risk of symptomatic Omicron infection. This might be due to some  
183 residual neutralization activity, or that anti-spike IgG recognizes the virus beyond neutralization  
184 via Fc-effector mechanisms as recently suggested [9]. Protection can be achieved by prior  
185 infection (irrespective of the vaccination status, Table) or by recent vaccination, with participants  
186 who were unvaccinated or those who received a single dose of Ad26.COV.2, most of whom  
187 more than eight months prior, showing significantly lower levels of anti-spike IgG.

188 A limitation of our study was that prior infection was assessed by NAAT only, with some  
189 unvaccinated participants with no previous NAAT-confirmed infection being seropositive for  
190 anti-spike antibody, demonstrating exposure to SARS-CoV-2 before blood collection. A high  
191 SARS-CoV-2 seropositivity in South Africa prior to the Omicron wave, has actually been  
192 suggested as a plausible explanation for the disconnection between hospitalization/death rates  
193 and infection rates associated with Omicron in the country [4].

194 We found high reinfection and vaccine breakthrough infection rates with the Omicron variant  
195 among HCW at three hospitals in Johannesburg, South Africa. Inherently, either natural infection  
196 or vaccination elicits immune responses that decays over time, with the specificity (cross-  
197 immunity), quality (neutralization) and magnitude (absolute amount) of circulating antibodies  
198 determining the likelihood of future symptomatic infections. Although a study from the United

199 Kingdom showed limited protection against symptomatic Omicron illness after BNT162b2 or  
200 ChAdOx1 vaccination [10], recent results on the vaccine effectiveness of Ad26.COV.2 booster  
201 dose in South Africa against Omicron hospitalization also demonstrates the value of booster  
202 vaccinations [2].

203 **Acknowledgements:** The authors would like to express special appreciation to the study  
204 participants and all the healthcare workers at Chris Hani Baragwanath Academic Hospital,  
205 Charlotte Maxeke Johannesburg Academic Hospital, and Helen Joseph Hospital and to the Wits  
206 VIDA staff.

207 Wits VIDA HCW Study Group: Yasmin Adam, Ziyaad Dangor, David P. Moore, Charl Verwey,  
208 Sithembiso C. Velaphi, Firdose Nakwa, Rudo Mathivha, Kavita Makan, Colin Menezes, Merika  
209 Tsitsi, Temnewo Habte, Jeremy Nel, William Malebati, Mervin Mer, Adam Mohamed, Rajen  
210 Morar, Palesa Motshabi Chakane, Thendo Mpapele, Feroza Motara, Dalubuhle Ndiweni, Debbie  
211 White, Farzanah Laher, Shakeel McKenzie, Sihle Mtshali.

212 **Table 1.** Healthcare workers presenting for at least one symptomatic study visit between 24<sup>th</sup>  
 213 November and 31<sup>st</sup> December 2021

	Symptomatic study visits 433		
	Omicron infection N=190 (43.9%)	NAAT negative, no Omicron infection N=243 238 (56.1%)	p-value
Race			0.68
Black-African	172 (90.5)	217 (89.3)	
Other	18 (9.5)	26 (10.7)	
Female	154 (81.5)	203 (83.5)	0.58
Mean age in years (SD)	37.4 (9.2)	38.0 (10.0)	0.50
Study site			0.005
CHBAH	156 (82.)	185 (76.1)	
HJH	15 (7.9)	9 (3.7)	
CMJAH	19 (10.0)	49 (20.2)	
No vaccine	32 (16.8)	37 (15.2)	0.72
Ad26.COV.2 single dose <sup>a</sup>	121 (63.9)	149 (61.3)	
Ad26.COV.2 booster dose <sup>b</sup>	21 (11.1)	28 (11.5)	
BNT162b2 <sup>c</sup>	9 (4.7)	17 (7.0)	
Median time in days from 1 <sup>st</sup> Ad26.COV.2 dose to visit (IQR)	280 (260, 287)	279 (257, 287)	0.70
Median time in days from Ad26.COV.2 booster dose to visit (IQR)	23 (18, 32)	22 (19, 35)	0.74
Previously SARS-CoV-2 NAAT- confirmed infection	53 (27.9)	101 (41.6)	0.003
Never infected	137 (72.)	142 (58.4)	
1 <sup>st</sup> wave <sup>d</sup>	32 (16.8)	48 (19.8)	0.018
2 <sup>nd</sup> wave <sup>d</sup>	8 (4.2)	15 (6.2)	
3 <sup>rd</sup> wave <sup>d</sup>	13 (6.8)	36 (14.8)	
Previously infected >1	0	2 (0.8)	
	N=174 <sup>e</sup>	N=215 <sup>e</sup>	
No Ad26.COV.2, no previous SARS- CoV-2 NAAT-confirmed infection	23 (13.2)	23 (10.8)	0.18
No Ad26.COV.2, previous SARS- CoV-2 NAAT-confirmed infection	9 (5.2)	14 (6.5)	
Ad26.COV.2, no previous SARS-	99 (56.9)	104 (48.6)	

CoV-2 NAAT-confirmed infection			
Ad26.COV.2, previous SARS-CoV-2 NAAT-confirmed infection	43 (24.7)	73 (34.1)	
	N=123	N=144	
Anti-spike IgG binding antibody units >32/mL	113 (91.9)	134 (93.1)	0.71
Anti-spike IgG geometric mean units (95% CI)	577 (428, 780)	968 (755, 1242)	0.009
Mean time in days from blood collection to visit (SD)	6.6 (17.8)	8.2 (19.3)	0.47
Serology results excluding bloods collected at the time of the current visit	N=28	N=37	
Anti-spike IgG binding antibody units >32/mL	25 (89.3)	35 (94.6)	0.64
Anti-spike IgG geometric mean units (95% CI)	511 (312, 836)	919 (575, 1468)	0.09
Mean time in days from blood collection to visit (SD)	29.1 (27.3)	32.3 (26.1)	0.64

214

215 Results are n (%) unless stated otherwise.

216 CHBAH: Chris Hani Baragwanath Academic Hospital; HJH: Helen Joseph Hospital; CMJAH:  
 217 Charlotte Maxeke Johannesburg Academic Hospital; SD: standard deviation; IQR: interquartile  
 218 range; CI: confidence interval; NAAT: Nucleic Acid Amplification Test.

219 <sup>a</sup>Received a single Ad26.COV.2 vaccine dose  $\geq 14$  days before visit.

220 <sup>b</sup>Received a booster Ad26.COV.2 vaccine dose  $\geq 14$  days before visit.

221 <sup>c</sup>Received two BNT162b2 vaccine doses, with second dose  $\geq 14$  days before visit.

222 <sup>d</sup>1<sup>st</sup> wave: April to October 2020, 2<sup>nd</sup> wave: November 2020 to April 2021, 3<sup>rd</sup> wave May to  
 223 September 2021.

224 <sup>e</sup>Excluding participants who received any BNT162b2 vaccine or those receiving Ad26.COV.2  
 225 vaccine <14 days before visit.

226 **Table 2.** Protection against Omicron infection by vaccination or previous SARS-CoV-2 NAAT-confirmed infection

	Omicron infection	NAAT negative, no Omicron infection	Unadjusted OR (95%CI)	Adjusted OR (95%CI)
Never vaccinated	32	37	Reference	Reference
Ad26.COV.2 single dose <sup>a</sup>	121	149	0.94 (0.55, 1.60)	0.81 (0.46, 1.43) <sup>e</sup>
Ad26.COV.2 booster dose <sup>b</sup>	21	28	0.87 (0.41, 1.81)	0.94 (0.44, 2.03) <sup>e</sup>
BNT162b2 two doses <sup>c</sup>	9	17	0.61 (0.24, 1.56)	0.59 (0.23, 1.57) <sup>e</sup>
No previous SARS-CoV-2 NAAT-confirmed infection	137	142	Reference	Reference
Previous SARS-CoV-2 NAAT-confirmed infection	53	101	<b>0.54 (0.36, 0.82)</b>	<b>0.55 (0.36, 0.84)<sup>f</sup></b>
1 <sup>st</sup> wave <sup>d</sup>	32	48	0.69 (0.42, 1.15)	0.71 (0.42, 1.19) <sup>f</sup>
2 <sup>nd</sup> wave <sup>d</sup>	8	15	0.55 (0.23, 1.35)	0.49 (0.20, 1.23) <sup>f</sup>
3 <sup>rd</sup> wave <sup>d</sup>	13	36	<b>0.37 (0.19, 0.74)</b>	<b>0.40 (0.20, 0.80)<sup>f</sup></b>
No previous SARS-CoV-2 NAAT-confirmed infection, no vaccine	23	23	Reference	Reference
No previous SARS-CoV-2 NAAT-confirmed infection, Ad26.COV.2 single dose	85	91	0.93 (0.49, 1.79)	0.89 (0.46, 1.72) <sup>g</sup>
No previous SARS-CoV-2 NAAT-confirmed infection, Ad26.COV.2 booster dose	14	13	1,06 (0.42, 2.79)	n.a
Previous SARS-CoV-2 NAAT-confirmed infection, no vaccine	9	14	Reference	Reference
Previous SARS-CoV-2 NAAT-confirmed infection, Ad26.COV.2 single dose	36	58	0.97 (0.38, 2.46)	0.82 (0.28, 2.44) <sup>g</sup>

Previous SARS-CoV-2 NAAT-confirmed infection, Ad26.COV.2 booster dose	7	15	0.73 (0.21, 2.48)	0.55 (0.14, 2.09) <sup>g</sup>
<b>Using antibody information and threshold from the conditional inference tree</b>				
No previous SARS-CoV-2 NAAT-confirmed infection, no vaccine, IgG <300 <sup>h</sup>	18	15	Reference	Reference
No previous SARS-CoV-2 NAAT-confirmed infection, Ad26.COV.2 single dose, IgG >1549 <sup>i</sup>	34	63	<b>0.45 (0.20, 1.00)</b>	<b>0.42 (0.18, 0.85)<sup>g</sup></b>
No previous SARS-CoV-2 NAAT-confirmed infection, Ad26.COV.2 booster dose, IgG >1549 <sup>i</sup>	10	11	0.76 (0.25, 2.27)	n.a

227

228 OR: Odds Ratio; CI: Confidence Interval; NAAT: Nucleic Acid Amplification Test

229 <sup>a</sup>Received a single Ad26.COV.2 vaccine dose  $\geq 14$  days before visit.

230 <sup>b</sup>Received a booster Ad26.COV.2 vaccine dose  $\geq 14$  days before visit.

231 <sup>c</sup>Received two BNT162b2 vaccine doses, with second dose  $\geq 14$  days before visit.

232 <sup>d</sup>1<sup>st</sup> wave: April to October 2020, 2<sup>nd</sup> wave: November 2020 to April 2021, 3<sup>rd</sup> wave May to September 2021.

233 <sup>e</sup>Adjusted for study site and having a previous SARS-CoV-2 NAAT-confirmed infection.


234 <sup>f</sup>Adjusted for study site and vaccination.

235 <sup>g</sup>Adjusted for study site.


236 <sup>h</sup>Excluding participants with anti-spike IgG binding antibody units >300/mL, as this antibody level was the lowest quartile among  
 237 unvaccinated participants with prior SARS-CoV-2 NAAT-confirmed infection and as such a putative level for previous asymptomatic  
 238 infections.

239 <sup>i</sup>Excluding participants with anti-spike IgG binding antibody units <1549/mL, as this was the threshold suggestive of a significant  
 240 reduction in the risk of symptomatic Omicron infection among vaccinated participants without prior SARS-CoV-2 NAAT-confirmed  
 241 infection.


A



B



C



**Figure caption:**

Conditional inference of Omicron infection probability and anti-spike IgG levels by prior SARS-CoV-2 NAAT-confirmed infection

(A) Inferred significant splits in previous SARS-CoV-2 NAAT-confirmed cases and spike IgG levels impact on the probability of having an Omicron infection during the study period (indicated by the red bars). The tree was generated from a training set comprised of 90% of all visits with a known serological result. The algorithm's infection predictive power was measured to be 72% in the remaining 10% of the data. (B) Antibody density distributions for participants with either NAAT-confirmed Omicron infection (red line) or no infection (grey line) during the study period. The vertical black line corresponds to the threshold 1549 anti-spike IgG binding units that emerged from the analysis on panel A. (C) Anti-spike IgG levels by prior SARS-CoV-2 NAAT-confirmed infection and vaccination status. Kruskal-Wallis tests indicate significant differences in IgG concentrations between participants with different levels of prior infection ( $p=0.00015$ ), and with more doses of vaccination in those who were not previously exposed ( $p=0.000057$ ). A lower significance in differences in IgG concentration for groups with different vaccination status for those who had a prior confirmed SARS-CoV-2 infection ( $p=0.038$ ).

**Funding:** Funding statement: This study was supported by the European & Developing Countries Clinical Trials Partnership (grant number RIA2020EF-3020) and The Bill & Melinda Gates Foundation (grant number INV018148\_2020). There was also partial support from the Department of Science and Technology and National Research Foundation: South African Research Chair Initiative in Vaccine Preventable Diseases; and the South African Medical Research Council.

**Contributions:** MCN: conceptualize the study and the analysis, overall supervision of the project, data interpretation, wrote the first draft of the manuscript. SS: sample analysis, data analysis, manuscript revision; VB: sample analysis, data analysis, manuscript revision; GK: data interpretation, manuscript revision; RA: data analysis, data interpretation, writing. SAM: conceptualize the study, manuscript revision.

**Conflicts of Interest:** MCN reports grants from the Bill & Melinda Gates Foundation, European & Developing Countries Clinical Trials Partnership, Pfizer, AstraZeneca and Sanofi-Pasteur; and personal fees from Pfizer and Sanofi-Pasteur. SAM reports grants and personal fees from the Bill & Melinda Gates Foundation, grants from the South African Medical Research Council, Novavax, Pfizer, Minervax, and European & Developing Countries Clinical Trials Partnership. GK reports grants from the Bill & Melinda Gates Foundation.

**Ethical considerations:** The study was approved by the Human Research Ethics Committee of the University of the Witwatersrand (reference number 200405) and conducted in accordance with Good Clinical Practice guidelines. All study participants provided written informed consent.

## References:

1. <https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/sars-cov-2-genomic-surveillance-update/>.
2. Gray, G.E., et al., *Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COVID during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study*. 2021: p. 2021.12.28.21268436.
3. Nunes, M.C., et al., *Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers in South Africa: A Longitudinal Cohort Study*. Clin Infect Dis, 2021. **73**(10): p. 1896-1900.
4. Madhi, S.A., et al., *South African Population Immunity and Severe Covid-19 with Omicron Variant*. 2021: p. 2021.12.20.21268096.
5. Kwatra, G., et al., *Correlation of dried blood spots and plasma for quantification of Immunoglobulin (IgG) against Receptor binding domain and full length spike protein of SARS-CoV-2*. J Virol Methods, 2022. **300**: p. 114394.
6. Hothorn, T., K. Hornik, and A. Zeileis, *Unbiased Recursive Partitioning: A Conditional Inference Framework*. Journal of Computational and Graphical Statistics, 2006. **15**(3): p. 651-674.
7. Altarawneh, H., et al., *Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant*. 2022: p. 2022.01.05.22268782.
8. Dejnirattisai, W., et al., *Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses*. bioRxiv, 2021.
9. Bartsch, Y., et al., *Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms*. medRxiv, 2021.
10. Andrews, N., et al., *Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern*. 2021: p. 2021.12.14.21267615.